Sector News

Nobel Prize in chemistry awarded to biotech founder Bertozzi, two others

October 8, 2022
Life sciences

Carolyn Bertozzi, a Stanford professor and serial biotech founder, has been awarded this year’s Nobel Prize in chemistry along with two other scientists, the Royal Swedish Academy of Sciences announced Wednesday.

She shares her prize with Morten Meldal, of the University of Copenhagen in Denmark, and K. Barry Sharpless, a former Nobel prize winner from the Scripps Research Institute in California. Meldal and Sharpless pioneered the concept of “click chemistry,” an idea describing how molecular building blocks snap together in chemical reactions.

Bertozzi took their work one step further, developing “bioorthogonal” click reactions that work inside living cells and don’t disrupt the cell’s normal chemistry. Her approach is used globally to map out cells and track biological processes, the academy said, and is behind targeted cancer treatments now being developed.

Bertozzi has also made a name for herself within the biotech industry, co-founding at least seven companies within the past 12 years. According to an interview with C&EN, her entrepreneurial push came when one of her graduate students asked for guidance in launching a company. Since then, she has continued to help launch startups based on technologies coming out of her laboratory at Stanford. The biotechs share a common foundation built on her work mapping sugar molecules called glycans that are found on cell surfaces, C&EN wrote. READ MORE

By Delilah Alvarado


comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.